Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.
YahooyesterdayKRYS
Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
YahooyesterdayKRYS
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled at 3:55 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 3:55 pm ET on Thursday, September 10, 2026 and will be posted on the Investors secti
YahooyesterdayKRYS
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo2 days agoKRYS
INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment
INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis. Read more on INMB stock here.
SeekingAlpha7 days agoKRYS
Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.97% on an annualized basis producing an average annual return of 44.08%. Currently, Krystal Biotech has a market capitalization of
Benzinga9 days agoKRYS
Krystal Biotech (NASDAQ:KRYS) Clears Minervini Trend Template and High Growth Momentum Screen
Krystal Biotech (KRYS) meets Minervini's Trend Template & High Growth Momentum screens: strong uptrend, high relative strength, and robust growth.
ChartMill13 days agoKRYS
Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says
Krystal Biotech (KRYS) has further room for gains driven by Vyjuvek, its treatment for the rare blis
Yahoo21 days agoKRYS
Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More
Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks, bonds, oil, and crypto all at once.
Yahoo21 days agoKRYS
RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400
RBC Capital analyst Lisa Walter initiates coverage on Krystal Biotech (NASDAQ:KRYS) with a Outperform rating and announces Price Target of $400.
Benzinga21 days agoKRYS
Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript
VYJUVEK revenue surged 24% as the company eyes a multiproduct pipeline transition.
Yahoo24 days agoKRYS
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.0% on an annualized basis producing an average annual return of 42.63%. Currently, Krystal Biotech has a market capitalization of
Benzinga25 days agoKRYS
Krystal Biotech (KRYS) Stock May Be Fully Valued After Its 5x Run
Krystal Biotech stock has delivered a very large 5 year return while recent valuation checks and the latest share price action suggest the current market price may already be baking in high expectations. Krystal Biotech has returned roughly 5x over the past 5 years, which puts extra focus on whether the current share price still offers an appealing entry point or mainly reflects past success. Ongoing adoption of its genetic medicine platform can support the current valuation, while concerns...
Yahoo25 days agoKRYS